HealthExec April 9, 2024
The results of the inaugural Medicare drug price negotiations later this year will have implications beyond setting the price CMS pays for the first 10 drugs to go through the process. It will also set the tone for future rounds of negotiations and set expectations for drugmakers.
That’s why CMS must ensure transparency, clarity and predictability by providing detailed guidance on comparator drug selection and the evaluation of evidence, according to health policy researchers at the D.C.-based Duke-Margolis Center for Health Policy.
“CMS’s choices about the negotiation framework will be revealed in real time, setting precedence for future years and sending powerful signals to the pharmaceutical industry about investment priorities,” Nitzan Arad, LLM, and colleagues write in an opinion...
Today's Sponsors
Today's Sponsor